New York, United States, April 4, 2024 (GLOBE NEWSWIRE) — Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve adequate biodistribution and related dose distribution to provide successful therapy without producing serious short- or long-term side effects. Due to their high rates of cell death, alpha particles in medical procedures are more destructive to tumor cells than beta particles. Consequently, they cause less damage to nearby healthy tissues. Radium, lead and bismuth are some radionuclides used in the therapeutic process.
Download Free Sample Report in PDF @ https://straitsresearch.com/report/alpha-emitter-market/request-sample
Rising prevalence of cancer drives global market
As the incidence of cancer increases, targeted/alpha anticancer therapy (TAT) is becoming increasingly popular. Radioimmunotherapy using high-efficiency, short-range particles has shown promise in treating several chronic diseases. In targeted therapy, the particles' ability to kill cells is exceptional. Radiotherapy with alpha emitters is beneficial for the treatment of chronic diseases. Cancer is the second most common cause of death worldwide, behind heart disease. Alpha particles are a more direct treatment method, delivering energy directly to the cells' DNA and fatally sabotaging chemical reactions. In addition to being investigated for various cancers, it is highly sought after to treat prostate cancer that has spread to the bones. Nearby healthy tissue may suffer less damage from alpha emitters. Therefore, it is anticipated that during the projection period the considered industry will proliferate.
Increased awareness of the potential benefits of targeted alpha therapy creates enormous opportunities
Targeted alpha/anticancer treatment (TAT) is becoming increasingly popular as cancer incidence increases. Medical experts and scientific communities around the world are increasingly aware of the potential benefits of using personalized medicines to treat certain conditions. Targeted therapy has been the focus of significant studies because of this increased awareness. The numerous components of this therapy are still being studied. Targeted alpha therapy is currently being tested in several clinical trials and has shown promise in the treatment of disseminated and micrometastatic malignancies without serious or unavoidable effects. Because they offer a rapid and painless process, nuclear medicines represent a promising market for early detection and imaging of numerous diseases.
Regional Analysis
North America is the largest revenue contributor and is expected to grow at a CAGR of 14.37% during the forecast period. The United States holds the largest proportion of the investigated market due to the existence of important market participants and the increasing prevalence of infectious and chronic diseases. The country also has the most established domestic suppliers of commercial radioactive raw materials and the largest number of foreign suppliers. The increase in cases of cancer and chronic neurological diseases is the main factor driving the growth of the market in the United States. For example, Bayer AG's 223RaCl2 (Xofigo) product was the first alpha-emitting radioisotope licensed in the US for palliative therapy of bone metastases from prostate cancer using indirect physiologic targeting. Canada's particle accelerator centre, which primarily employs At-211 and A-209 and is funded by the Canadian Cancer Society Innovation, is one of the largest alpha therapy research centres. The country's main nuclear research and technology facility, Canadian Nuclear Laboratories (CNL), has also increased its attempts to create TAT agents.
Europe is expected to grow at a CAGR of 15.38% during the forecast period. The key Factors driving the alpha issuer market in the UK. are the increasing prevalence of chronic and infectious diseases and the expansion of radiopharmaceutical research and development. Many companies are launching projects to use radiopharmaceuticals to cure diseases such as cancer. Ra-223, Bi-213 and Pb-212 are the main areas of research in the aforementioned European countries. Since Bayer's drug has been available in the European Union for five years, the rest of Europe, especially Norway and the Benelux countries, have become the drug's largest partner.
Key points
- Based on radionuclides, the global alpha emitters market is bifurcated into radium (Ra-223), actinium (Ac-225) and lead (Pb-212). The radio (Ra-223) segment is the largest contributor to the market and is estimated to grow at a CAGR of 3.22% during the forecast period.
- Based on medical applications, the global alpha emitter market is divided into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors, and other medical applications. The prostate cancer segment is the largest contributor to the market and is estimated to grow at a CAGR of 4.34% during the forecast period.
- North America is the largest revenue contributor and is expected to grow at a CAGR of 14.37% during the forecast period.
Competitive players
The major key players in the global alpha emitter market are Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Fusion Pharmaceuticals, Novartis Ag (Endocyte Inc.), Orano Group (Orano Med) and Telix Pharmaceuticals Ltd..
Market news
- In August 2022, Alpha Tau Medical Ltd.s, the developer of the innovative alpha radiation cancer therapy Alpha DaRT, reported second quarter 2022 financial results and provided a corporate update.
- In November 2022, Actinium announced positive 1- and 2-year overall survival data for patients with relapsed or refractory acute myeloid leukemia in the Phase 1 Actimab-A CLAG-M combination trial.
Global Alpha Emitter Market: Segmentation
By radionuclide
- Radium (Ra-223)
- Actinium (Ac-225)
- Lead (Pb-212)
For medical applications
- prostate cancer
- bone metastases
- Ovarian cancer
- Pancreatic cancer
- Endocrine tumors
- Other medical applications
By regions
- North America
- Europe
- Pacific Asia
- LAMEA
Get detailed market segmentation @ https://straitsresearch.com/report/alpha-emitter-market/segmentation
About Straits Research Pvt. Ltd. Limited.
Straits Research is a market intelligence company providing global business information reports and services. Our unique combination of quantitative forecasting and trend analysis provides forward-looking information for thousands of decision makers. Strait Research Pvt. Limited. Ltd. provides actionable market research data, specially designed and presented for decision making and ROI.
Whether it is commercial sectors in the nearest city or on other continents, we understand the importance of knowing the customer's purchase. We overcome our clients' problems by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a combination of market research and business approaches.
For more information about your target market, please contact us below:
Phone: +1 646 905 0080 (USA)
+91 8087085354 (India)
+44 203 695 0070 (United Kingdom)
Email: sales@straitsresearch.com
Follow us: LinkedIn | Facebook | instagram | Twitter
